Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DefiniGEN Joins European Bank for Induced Pluripotent Stem Cells (EBiSC) Consortium

Published: Wednesday, August 27, 2014
Last Updated: Wednesday, August 27, 2014
Bookmark and Share
EFPIA pharmaceutical companies, SMEs, and academia join together in an IMI supported public-private partnership project to establish the leading facility for the storage and distribution of induced pluripotent stem (iPS) cells in Europe.

DefiniGEN Ltd today announced it has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).  The EBiSC iPS cell bank will act as a central storage and distribution facility for human iPS cells, to be used by researchers across academia and industry in the study of disease and the development of new therapeutics. DefiniGEN’s role will be to validate EBiSC iPS cell lines by generating liver hepatocyte cells for toxicology, disease modelling, and regenerative medicine applications.

Dr Marcus Yeo, CEO of DefiniGEN, said: “We are delighted to be a part of this ground-breaking consortium which will provide a crucial platform resource to enable the realisation of the full potential of iPS technology.”       

Conceptualised  and coordinated by Pfizer Ltd in Cambridge, UK and managed by Roslin Cells Ltd in Edinburgh, the EBiSC bank aims to become the European ”go to” resource for high quality research grade human iPS cells. Today, iPS cells are being created in an increasing number of research programmes underway in Europe, but are not being systematically catalogued and distributed at the necessary scale to keep pace with their generation, nor to meet future demand. The €35 million project will support the initial build of a robust, reliable supply chain from the generation of customised cell lines, the specification to internationally accepted quality criteria and their distribution to any global qualified user, ensuring accessibility to consistent, high quality tools for new medicines development.

Ruth McKernan, CSO of Pfizer’s Neusentis research unit, said: “We are excited to be a part of this precompetitive collaboration to build a sustainable repository of high quality human iPS cell lines. For many areas of research in academia and in industry, understanding the biological basis of disease heterogeneity is the next horizon. A bank of well-characterised iPS lines with strong relevance to the entire research community will help us all in our mission to bring therapies to patients.”

Since their discovery by Shinya Yamanaka in 2006, iPS cells have been recognised as a break-through technology which is leading to new approaches for the development of medical therapies and for the understanding of genetic diseases. iPS cells are produced in research laboratories by “reprogramming” cells provided by individual donors with appropriate consent, typically skin or certain blood cells. The iPS cells created will then replicate indefinitely or, under controlled conditions, can be “differentiated” into any other cell type such as nerve, heart or liver cells.  Researchers are able to use these cells to test how different patients might respond to new drugs or to analyse how genetic diseases develop. iPS cells are particularly important for research on diseases for which it is not possible to obtain relevant tissue samples from living patients – such as neurodegenerative diseases including Alzheimer’s and Huntington’s Disease.

Numerous research programmes are currently underway in Europe to produce iPS cells from hundreds of different donors. Each programme has its own research goal, but as the iPS cells can be replicated to produce more cells than needed by the project, they could also be used by other researchers. However, the individual projects do not have the financial, technical or human resources to distribute cells to other researchers.  This is the task which EBiSC is being established to address.

Aidan Courtney, CEO of Roslin Cells, said: “The consortium includes many of Europe’s leading stem cell scientists and experts in related fields such as data management, law and social sciences. This breadth of expertise will allow EBiSC to establish rigorous methods to ensure that the cells distributed to researchers meet internationally recognised standards and also that their use is consistent with the consent of the tissue donor and the national laws of the country in which the iPS cells were originally generated.  We will keep abreast of the fast moving progress in the field of how to make these cells and also provide an on-line resource to pool the results of research undertaken with the catalogue items that we distribute. In this way, EBiSC will create an ever increasing wealth of iPS cells, data and knowledge, which will help advancing drug development and health research.”  


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DefiniGEN Raises £1.5M
Company has announced that the investment will be used to fund commercial launch of new pancreatic and lung stem cell products for drug discovery and regenerative medicine.
Monday, May 23, 2016
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Defining Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
Topical Immunotherapy Effective Against Early Skin Cancer
Combination of two commonly used drugs triggers immune response against precancerous skin lesions.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!